Literature DB >> 4039120

Penetration of aztreonam into human bronchial secretions.

D L Bechard, S S Hawkins, R Dhruv, L T Friedhoff.   

Abstract

Nine intubated patients were given a single, 2-g intravenous dose of aztreonam over 5 min. Samples of serum and bronchial secretion were obtained 2, 4, and 8 h after administration and assayed for aztreonam content. The mean concentrations in bronchial secretion ranged from 1.9 to 5.2 micrograms/ml and tended to be highest at 4 h. The concentrations in bronchial secretion varied from patient to patient, but each patient had one or more bronchial secretion samples that contained at least 2.7 micrograms of drug per ml.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039120      PMCID: PMC176250          DOI: 10.1128/AAC.27.2.263

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Penetration of antimicrobial agents into bronchial secretions.

Authors:  G A Wong; T H Pierce; E Goldstein; P D Hoeprich
Journal:  Am J Med       Date:  1975-08       Impact factor: 4.965

2.  Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

Authors:  R B Sykes; D P Bonner; K Bush; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

3.  Pharmacokinetics and tissue penetration of azthreonam.

Authors:  R Wise; A Dyas; A Hegarty; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

  3 in total
  8 in total

1.  Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

2.  Penetration of pefloxacin into bronchial secretions.

Authors:  G Bonmarchand; J J Grès; G Lerebours; P Massari; J J Mayoux; A Montay; J Leroy
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 3.  Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

Review 4.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of aztreonam.

Authors:  H Mattie
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

7.  Aztreonam concentrations in human tissues obtained during thoracic and gynecologic surgery.

Authors:  T R Beam; R P Galask; L T Friedhoff; T B Platt; M A Leitz
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

8.  Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.

Authors:  Stephen Kirkby; Kimberly Novak; Karen McCoy
Journal:  Core Evid       Date:  2011-08-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.